GSK presents promising late-stage lung cancer data from two investigational drugs

GSK highlighted late-stage results for two of its lung cancer candidates, reporting encouraging efficacy signals that could advance the programs toward regulatory review.

The company shared the data in a recent briefing, emphasizing the potential impact on treatment options for patients with advanced disease.

In separate biotech updates, Definium announced that its LSD therapy showed strong performance in a pivotal anxiety disorder trial, suggesting a possible new avenue for mental health treatment.

AstraZeneca, meanwhile, reported that its breast cancer drug failed to achieve a key trial endpoint, marking a setback for the oncology pipeline.

These mixed outcomes illustrate the dynamic landscape of drug development, where advances in one area can be offset by challenges in another.